<DOC>
	<DOC>NCT02585869</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of gemcabene on HDL‐C, LDL‐C, TG, and other lipid levels in patients with low HDL‐C</brief_summary>
	<brief_title>Efficacy and Safety of Gemcabene in Patients With Low HDL‐C and Either Normal or Elevated Triglycerides</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Men or naturally postmenopausal or surgically menopausal women 18 to 80 years of age Baseline HDL‐C &lt;35 mg/dL (0.9 mmol/L) Creatine phosphokinase (CPK) &gt;3 × the upper limit of normal (ULN) Body Mass Index (BMI) &gt;35 kg/m2 Uncontrolled Hypertension &gt;95 mm Hg Uncontrolled diabetes mellitus (HbA1c &gt;10%) Renal dysfunction (blood urea nitrogen [BUN] or creatinine &gt;2 × ULN); Hepatic dysfunction (aspartate aminotransferase [AST] or alanine aminotransferase [ALT] &gt;2 × ULN) Uncontrolled hypothyroidism (TSH &gt;1.5 × ULN) Myocardial infarction, severe or unstable angina pectoris, coronary angioplasty, coronary artery bypass graft, or any other major cardiovascular event resulting in hospitalization in previous 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Lipid Regulator</keyword>
	<keyword>TG</keyword>
</DOC>